Q1 2023

Filed May 15, 2023 · 10-Q · 45 days after period end · 0001477932-23-003493

Q1 2023 · 10-Q

Revenue

$22.00K

+340.0% vs Q1 2022

Net Income

-$869.00K

N/M vs Q1 2022

EPS Diluted

-$0.02

N/M vs Q1 2022

Gross Profit$13,000+225.0%

Operating Income

Same quarter

Metric	Q1 2023	Q1 2022	Q1 2021	Q1 2020
Revenue	$22.00K	$5.00K	$0.00	$0.00
Net Income	-$869.00K	-$507.00K	-$603.00K	$2.73M
EPS Diluted	-$0.02	-$0.05	-$0.04	$0.04

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR